801 West Capital Management, LLC

801 West Capital Management manages private pooled investment vehicles and serves as the general partner and investment manager to several onshore and offshore funds, and as a sub‑adviser to a series fund; it does not provide advisory services to individual retail clients. The firm is compensated primarily through fees based on assets under management and, as of December 31, 2025, managed roughly $516 million in discretionary assets.

The firm operates a fund‑of‑funds model, allocating capital to multiple Underlying Funds and managers—generally targeting diversified hedge fund styles and managers that employ deep fundamental research and may be closed to outside investors. 801 West emphasizes extensive investment and operational due diligence, negotiates investment terms, structures mini‑master arrangements for certain onshore/offshore pairs, and performs ongoing monitoring of Underlying Managers.

Distinctive aspects include the firm’s reliance on CFTC exemptions for its fund‑of‑funds activities—disclosing use of a historical CFTC no‑action letter and annual reaffirmation under CFTC Rule 4.13(a)(3)—a regulatory stance that is less common among peers. The firm also launched a Biotech Series in 2025 that invests via a separately managed account overseen by Palo Alto Investors and typically holds a concentrated portfolio of about five to ten biotech positions, and it waives management and performance fees on inter‑fund investments among its funds.